About Abzena
Abzena is a company based in Cambridge (United Kingdom) founded in 2001 was acquired by Welsh, Carson, Anderson & Stowe in August 2018.. Abzena has raised $67.11 million across 11 funding rounds from investors including Mercia, Welsh, Carson, Anderson & Stowe and YFM Equity Partners. The company has 306 employees as of December 31, 2020. Abzena has completed 1 acquisition, including PacificGMP. Abzena offers products and services including Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development. Abzena operates in a competitive market with competitors including Syngene, Patheon, Piramal Group, Maravai Life Sciences and LakePharma, among others.
- Headquarter Cambridge, United Kingdom
- Employees 306 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Abzena Limited
- Date of Incorporation 25 Mar, 2014
- Jurisdiction CAMBRIDGE
-
Annual Revenue
$22.12 M (USD)119as on Dec 31, 2016
-
Net Profit
$-41.47 M (USD)0as on Dec 31, 2019
-
EBITDA
-
Total Equity Funding
$67.11 M (USD)
in 11 rounds
-
Latest Funding Round
$65 M (USD), Post-IPO
Mar 31, 2022
-
Investors
Mercia
& 8 more
-
Employee Count
306
as on Dec 31, 2020
- Investments & Acquisitions
-
Acquired by
Welsh, Carson, Anderson & Stowe
(Aug 16, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Abzena
Abzena offers a comprehensive portfolio of products and services, including Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Service for identifying high-affinity antibodies with desired activity.
Development of ADCs and related conjugates for targeted therapies.
Generation of cell lines for biologics production and GMP processes.
Optimization of formulations for monoclonal antibodies and conjugates.
Unlock access to complete
Funding Insights of Abzena
Abzena has successfully raised a total of $67.11M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $65 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Post-IPO — $65.0M
-
First Round
First Round
(20 Jun 2007)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2022 | Amount | Post-IPO - Abzena | Valuation |
investors |
|
| Jul, 2020 | Amount | Post-IPO - Abzena | Valuation |
investors |
|
| Apr, 2017 | Amount | Post-IPO - Abzena | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Abzena
Abzena has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, Welsh, Carson, Anderson & Stowe and YFM Equity Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare and technology sectors are targeted for private equity investments.
|
Founded Year | Domain | Location | |
|
Biospring is engaged in partnering with pharma services businesses.
|
Founded Year | Domain | Location | |
|
Investments in startups are focused on Europe and the US.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Abzena
Abzena has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include PacificGMP. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Contract manufacturing in cGMP and non-GMP biologics is provided.
|
2005 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Abzena
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Abzena Comparisons
Competitors of Abzena
Abzena operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Syngene, Patheon, Piramal Group, Maravai Life Sciences and LakePharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of contract research and manufacturing services for both small molecules and biologics
|
|
| domain | founded_year | HQ Location |
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
|
|
| domain | founded_year | HQ Location |
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
|
|
| domain | founded_year | HQ Location |
Provides enabling tools and services in the life sciences research and bio-production industries
|
|
| domain | founded_year | HQ Location |
Provider of drug discovery on molecular biology, viral vectors and cell & protein engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Abzena
Frequently Asked Questions about Abzena
When was Abzena founded?
Abzena was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Where is Abzena located?
Abzena is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Who is the current CEO of Abzena?
Jonathan Goldman is the current CEO of Abzena.
Is Abzena a funded company?
Abzena is a funded company, having raised a total of $67.11M across 11 funding rounds to date. The company's 1st funding round was a Post-IPO of $3.71M, raised on Jun 20, 2007.
How many employees does Abzena have?
As of Dec 31, 2020, the latest employee count at Abzena is 306.
What is the annual revenue of Abzena?
Annual revenue of Abzena is $22.12M as on Dec 31, 2016.
What does Abzena do?
Abzena was founded in 2001 and is headquartered in Cambridge, United Kingdom. Operations focus on the biotechnology sector, where services in antibody discovery, cell line development, and bio analytics are delivered. Additional offerings include proprietary technologies, mammalian and bio conjugates manufacturing, peptide synthesis, analytical development, and bio assays to support pharmaceutical and research needs.
Who are the top competitors of Abzena?
Abzena's top competitors include Syngene, Grand River Aseptic Manufacturing and Patheon.
What products or services does Abzena offer?
Abzena offers Antibody Discovery, Bioconjugate Development, Cell Line Development, and Formulation Development.
How many acquisitions has Abzena made?
Abzena has made 1 acquisition, including PacificGMP.
Who are Abzena's investors?
Abzena has 9 investors. Key investors include Mercia, Welsh, Carson, Anderson & Stowe, YFM Equity Partners, Invesco Perpetual, and Imperial Innovations.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.